Impact of Diffusing Lung Capacity for Carbon Monoxide on Mortality Risk in Patients with ASMD: Insights from a Post Hoc Analysis. [PDF]
Wuyts WA +7 more
europepmc +1 more source
Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt: A prospective, observational cohort study with an interventional subgroup. [PDF]
Arafa NA, Mahfouz A, Anwar S, Marzouk I.
europepmc +1 more source
The Acid sphingomyelinase/ceramide System in Idiopathic Inflammatory Myopathies: a Potential Treatment Target. [PDF]
Chen Y, Yang J, Yin G, Xie Q.
europepmc +1 more source
Improvement in quality of life and general functions in pediatric acid sphingomyelinase deficiency patients after receiving olipudase alfa: A single-center experience in Taiwan. [PDF]
Pan YW, Yu WH, Tsai MC, Chou YY.
europepmc +1 more source
Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomyelinase Deficiency in Taiwan. [PDF]
Lin HH +10 more
europepmc +1 more source
Sphingolipids associated research in Alzheimer's disease: an explored trends analysis. [PDF]
Xie MR, Chen YJ, Yuan H.
europepmc +1 more source
Secretory Acid Sphingomyelinase in Children and Adolescents With Type 1 Diabetes. [PDF]
Mameli C +12 more
europepmc +1 more source
Glioblastoma Cells Expressing Oncogenic EGFR Release Multiple Extracellular Vesicle Subpopulations Positive or Negative for EGFR. [PDF]
Pishavar E +8 more
europepmc +1 more source
A Retrospective Chart Review Study on the Burden of Illness of Acid Sphingomyelinase Deficiency in Brazil. [PDF]
Giugliani R +13 more
europepmc +1 more source
Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results. [PDF]
Wasserstein MP +20 more
europepmc +1 more source

